Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2010
10/21/2010US20100267817 Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
10/21/2010US20100267809 Double stranded nucleic acid targeting low copy promoter-specific rna
10/21/2010US20100267799 Orodispersible pharmaceutical composition of perindopril
10/21/2010US20100267798 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/21/2010US20100267793 Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267783 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
10/21/2010US20100267778 Diphenyl ether compound, process for producing the same, and use
10/21/2010US20100267773 Estrogen receptor ligands and methods of use thereof
10/21/2010US20100267755 Pyrimidine derivatives
10/21/2010US20100267739 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
10/21/2010US20100267710 N3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267685 Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones
10/21/2010US20100267650 Dual Chain Synthetic Heparin-Binding Growth Factor Analogs
10/21/2010US20100267649 Vascular adhesion molecules and modulation of their function
10/21/2010US20100267636 Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267564 Method for encapsulating oils in an aqueous medium with hase polymer emulsions, products obtained, and uses thereof
10/21/2010US20100267140 Soluble inhibitors of vascular endothelial growth factor and use thereof
10/21/2010US20100266694 Chitosan/Carbon Nanotube Composite Scaffolds for Drug Delivery
10/21/2010US20100266685 Seamless Coated Spherical Filled Capsules
10/21/2010US20100266676 Nanocapsules with a liquid lipid core charged with water-soluble or water-dispersible active agents
10/21/2010US20100266660 Osteogenic Implants with Combined Implant Materials and Methods for Same
10/21/2010US20100266601 Antibodies that inhibit tslp activity
10/21/2010US20100266549 Novel probiotics for pet food applications
10/21/2010US20100266539 Chemokine receptor antagonist and medical use thereof
10/21/2010US20100266507 Luminescent compounds
10/21/2010DE69229688C5 Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten Containing ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
10/21/2010CA2758359A1 Fused pyrrolopyridine derivative
10/21/2010CA2758245A1 Gamma-amino-butyric acid derivatives as gabab receptor ligands
10/20/2010EP2241625A1 Proteinase K resistant surface protein of neisseria meningitidis
10/20/2010EP2241567A1 Bicycloamine derivative
10/20/2010EP2241564A1 3,8-diaminotetrahydroquinoline derivative
10/20/2010EP2241560A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
10/20/2010EP2241559A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
10/20/2010EP2241334A1 Method for determination of sensitivity to anti-cancer agent
10/20/2010EP2241333A1 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/20/2010EP2241315A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
10/20/2010EP2240175A2 Compounds with mdr1-inverse activity
10/20/2010EP1747778B1 Anti-fatigue composition
10/20/2010EP1418941B9 Inducted immune response against the feline immunodeficiency virus
10/20/2010EP1412484B1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering
10/20/2010EP1373502B1 Dopaminergic neuronal survival-promoting factors and uses thereof
10/20/2010EP1283832B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
10/20/2010EP1091938B1 Antihistaminic piperidine derivatives and intermediates for the preparation thereof
10/20/2010CN101868251A Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor
10/20/2010CN101868243A Aromatase inhibitor
10/20/2010CN101868237A Alpha7 nAChR agonists for treating or preventing metabolic disorders
10/20/2010CN101868230A Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine
10/20/2010CN101862456A Remedy
10/20/2010CN101862357A Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof
10/20/2010CN101862317A Pregabalin derivatives for the treatment of fibromyalgia and other disorders
10/20/2010CN101862312A New application of 6-gingerol
10/20/2010CN101862009A Health-care drink for eliminating hiccup, pain of chest and back and spasm of bowels and abdomen and preparation method
10/20/2010CN101164530B Aqueous solution containing stable sodium pyrouvate and preparing method and use thereof
10/19/2010US7816516 Reacting hydroxyalkyl starch (HAS) with the bioactive agent in a medium that includes water; drug-HAS conjugates for treating tumors, arrythmia, infectious diseases; bioavailability; nontoxic solvents; biodrug activity is not inactivated
10/19/2010US7816399 Synergistic combination of prostaglandin and nitric oxide donor compounds; ocular hypertension and glaucoma
10/19/2010US7816398 Fatty alcohol drug conjugates
10/19/2010US7816376 Use as excitatory amino acid antagonists for combating neurodegenerative and cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, or psychoses; for example, 3-[4-(3,4-methylenedioxybenzyl)piperidino]-N-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propionamide
10/19/2010US7816375 Ligands for monoamine receptors and transporters, and methods of use thereof
10/19/2010US7816373 administering polyethylene glycol or ethylene oxide-propylene oxide copolymers, with drugs, to improve delivery in the alimentary canal
10/19/2010US7816363 Inhibitors of histone deacetylase
10/19/2010US7816359 such as (4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide), used as antitumor agents
10/19/2010US7816340 Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid
10/19/2010US7816335 Therapeutic compounds and methods
10/19/2010US7816333 nucleosides such as 3',5'-di-O-Benzyl-2'-O,4'-C-ethylene-4-N-benzoylcytidine for treatment of pain, psoriasis, inflammatory disorders, infectious skin disease, skin cancer, Lyme disease, influenza virus, cytomegalovirus, herpes virus, herpes simplex virus, papilloma virus, Epstein Barr virus or HIV
10/19/2010US7816319 Methods and products for manipulating uncoupling protein expression
10/19/2010US7816317 Tripeptide prodrug compounds
10/19/2010US7816075 treating a human afflicted with condition characterized by elevated serum triglyceride or very low density lipoprotein (VLDL), comprising the step of administering an inhibitor of human delta-9 stearoyl-CoA desaturase (SCD1) activity; coronary artery disease, Type II diabetes, obesity
10/19/2010US7815937 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant
10/19/2010US7815909 human tumor necrosis factor alpha (TNF) inhibitors; for rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis
10/19/2010CA2614479C Derivatives of seleno-amino acids
10/19/2010CA2469346C Substituted 2-pyrrolidin-2-yl-1h-indole derivatives for treatment of migraine
10/19/2010CA2468314C The use of water-soluble lamarin in the treatment of cancer
10/19/2010CA2465471C Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
10/19/2010CA2464367C Bicyclic compounds
10/19/2010CA2463284C Pyrimidine compounds and pharmaceutical compositions containing the compounds
10/19/2010CA2456547C Process for preparing inhalable powders
10/19/2010CA2451422C Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
10/19/2010CA2448089C Thiolalkyl benzoic acid derivatives
10/19/2010CA2437409C Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/19/2010CA2437196C A composition for the treatment of heart failure comprising levosimendan and a calcium ion source and/or an intreacellular calcium increasing agent
10/19/2010CA2436526C Heterocyclic sulfonamide inhibitors of beta amyloid production
10/19/2010CA2433417C Novel 1,2-diphenylethene derivatives for treatment of immune diseases
10/19/2010CA2415577C Use of cox-2 inhibitors for preventing immunodeficiency
10/19/2010CA2409743C Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/19/2010CA2400667C Modified nodavirus rna for gene delivery
10/19/2010CA2399840C Use of roflumilast or pumafentrine in combination with methotrexate for the treatment of arthritic diseases
10/19/2010CA2397789C Novel human kinase protein and polynucleotides encoding the same
10/19/2010CA2393158C Substituted homopiperidinyl benzimidazole analogues as fundic relaxants
10/19/2010CA2380022C Aromatic esters of camptothecins and methods to treat cancers
10/19/2010CA2379988C Enzyme catalyzed therapeutic activation
10/19/2010CA2374631C Benzene derivatives, process for their preparation and pharmaceutical compositions containing them
10/19/2010CA2325803C Novel omega conotoxin peptides
10/19/2010CA2321455C Indole-3-propionic acids, salts and esters thereof used as medicaments
10/19/2010CA2309115C Use of cytokines and mitogens to inhibit pathological immune responses
10/19/2010CA2307842C Hyaluronan synthase gene and uses thereof
10/19/2010CA2286722C Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
10/19/2010CA2241179C Dry compositions
10/19/2010CA2214338C Use of .alpha.1l agonists for treating urinary incontinence
10/19/2010CA2186118C Compacted nucleic acids and their delivery to cells
1 ... 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 ... 1564